Sweden · Delayed Price · Currency is SEK Cereno Scientific AB Company Description
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden.
The company’s lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms.
Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases.
The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System.
Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.
| Country | Sweden |
| Founded | 2012 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Sten Sorensen |
Contact Details
Address: Förändringens gata 10 Gothenburg, 431 53 Sweden | |
| Phone | 46 768 66 77 87 |
| Website | cerenoscientific.com |
Stock Details
| Ticker Symbol | CRNO.B |
| Exchange | Nasdaq Stockholm |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sten R. Sorensen | Chief Executive Officer and Director |
| Eva Jagenheim | Chief Financial Officer |
| Dr. Bjorn Dahlof FACC, FESC, M.D., Ph.D. | Chief Scientific Officer |
| Tove Bergenholt | Head of IR and Communications |
| Fredrik Frick | Head of Clinical Operations |
| Nicholas Oakes | Head of Preclinical Development |
| Dr. Rahul Agrawal M.D. | Chief Medical Officer and Head of Research & Development |